Several other research analysts also recently weighed in on DBVT. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating and set a $10.00 target price for the company in a research note on Wednesday, April 10th. JMP Securities reissued a buy rating and issued a $20.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Goldman Sachs Group began coverage on shares of DBV TECHNOLOGIE/S in a research note on Monday, June 17th. They issued a buy rating and a $14.00 target price for the company. Finally, Stifel Nicolaus reissued a hold rating and issued a $10.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $14.67.
DBV TECHNOLOGIE/S stock opened at $8.67 on Friday. DBV TECHNOLOGIE/S has a 52 week low of $3.60 and a 52 week high of $25.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34. The stock has a 50-day simple moving average of $8.79.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: What is the QQQ ETF?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.